• PDF: Delivered by email usually within 12 to 24 UK business hours.

Edwards Lifesciences Corporation Product Pipeline Analysis

Edwards Lifesciences Corporation Product Pipeline Analysis

Edwards Lifesciences Corporation Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Scope's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

  • Details of development stage by sector and equipment type.
  • Pipeline products grouped by therapy area, development stage and trial phase.
  • Detailed information on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results.
  • Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
  • Product updates covering estimated approval dates and estimated launch dates.
  • Descriptions of novel technologies relating to pipeline products of the company.
  • Patents and patent applications covered for the product.
  • News updates on key events relating to the product and its development.

Reasons to buy

  • A single source to fulfill competitor information relating to products in development.
  • Identify pipeline products that are potential competitor to your product lines.
  • Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
  • Access clinical trial information to map trial results and plan targeted marketing activities.
  • Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
  • Identification of potential investment opportunities.
  • Build up knowledge base for potential distribution and marketing partners.
  • Helps avoid patent infringement.
  • Timelines from concept to market lets you keep track of market potential build for a new product.
  • Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

This report covers the following industry codes:

SIC Code: 3845

NAICS Code: 334517

  • 1.1 List of Tables
  • 1.2 List of Figures
  • 2 Company Snapshot
    • 2.1 Key Information
    • 2.2 Company Overview
  • 3 Edwards Lifesciences Corporation Pipeline Products
    • 3.1 Edwards Lifesciences Corporation Product Pipeline Analysis
      • 3.1.1 Edwards Lifesciences Corporation Pipeline Products By Equipment Type
      • 3.1.2 Edwards Lifesciences Corporation Pipeline Products By Development Stage
      • 3.1.3 Edwards Lifesciences Corporation Pipeline Products By Therapy Area
      • 3.1.4 Edwards Lifesciences Corporation Pipeline Products By Clinical Trials
      • 3.1.5 Edwards Lifesciences Corporation Pipeline Products By News Summary
    • 3.2 MONARC Mitral Repair System
      • 3.2.1 Product Status
      • 3.2.2 Product Description
      • 3.2.3 MONARC Mitral Repair SystemClinical Trials
      • 3.2.4 MONARC Mitral Repair SystemClinical Trials
      • 3.2.5 Product Patent Details
    • 3.3 MOBIUS Leaflet Repair System
      • 3.3.1 Product Status
      • 3.3.2 Product Description
      • 3.3.3 Product Milestone
      • 3.3.4 Clinical Trials
      • 3.3.5 Product Patent Details
    • 3.4 Edwards SAPIEN Transcatheter Heart Valve
      • 3.4.1 Product Status
      • 3.4.2 Product Description
      • 3.4.3 Product Milestone
      • 3.4.4 Edwards SAPIEN Transcatheter Heart ValveClinical Trials
      • 3.4.5 Edwards SAPIEN Transcatheter Heart ValveClinical Trials
      • 3.4.6 Edwards SAPIEN Transcatheter Heart ValveClinical Trials
      • 3.4.7 Edwards SAPIEN Transcatheter Heart ValveClinical Trials
    • 3.5 Carpentier-Edwards PERIMOUNT Magna Ease Aortic Heart Valve
      • 3.5.1 Product Status
      • 3.5.2 Product Description
      • 3.5.3 Product Milestone
      • 3.5.4 Product Patent Details
    • 3.6 Carpentier-Edwards BioPhysio aortic valve
      • 3.6.1 Product Status
      • 3.6.2 Product Description
      • 3.6.3 Product Milestone
      • 3.6.4 Clinical Trials
    • 3.7 Ascendra Transapical Delivery System
      • 3.7.1 Product Status
      • 3.7.2 Product Description
      • 3.7.3 Product Milestone
      • 3.7.4 Clinical Trials
      • 3.7.5 Product Patent Details
    • 3.8 Carpentier-Edwards Physio II ring
      • 3.8.1 Product Status
      • 3.8.2 Product Description
      • 3.8.3 Product Patent Details
    • 3.9 Carpentier-Edwards PERIMOUNT Magna aortic valve
      • 3.9.1 Product Status
      • 3.9.2 Product Description
      • 3.9.3 Product Milestone
      • 3.9.4 Product Patent Details
    • 3.10 Continous Glucose Monitoring Device
      • 3.10.1 Product Status
      • 3.10.2 Product Description
  • 4 Recent Developments
    • 4.1 Product News
      • 4.1.1 Oct 14, 2008: Survival Rates Rise In Studies Of Edwards Heart Valves
      • 4.1.2 Oct 13, 2008: Edwards Lifesciences' New Transcatheter Heart Valve Data Demonstrate Positive Results
      • 4.1.3 Sep 15, 2008: Edwards Lifesciences Presents New Transcatheter Heart Valve Data At EACTS
      • 4.1.4 Sep 03, 2008: Edwards Wins FDA Approval For Mitral Heart Valve
      • 4.1.5 May 12, 2008: Edwards Lifesciences Introduces New Transcatheter Valve Delivery System At EuroPCR 2008
      • 4.1.6 Apr 18, 2008: Edwards Lifesciences Announces First Implants In US Study Of Minimally-Invasive Pulmonic Valve
      • 4.1.7 Jan 29, 2008: Edwards Lifesciences Receives FDA Approval To Add Transapical Delivery System To US Clinical Trial Of Transcatheter Heart Valve
      • 4.1.8 Jan 04, 2008: Edwards SAPIEN Transcatheter Heart Valve Training Program Launches In Europe
      • 4.1.9 Dec 06, 2007: Edwards Lifesciences Receives European Approval For First Minimally Invasive Surgical Valve Replacement System
      • 4.1.10 Oct 23, 2007: Edwards Lifesciences: US may delay approval of new valves
      • 4.1.11 Oct 23, 2007: US May Delay Approval Of New Heart Valves
      • 4.1.12 Sep 13, 2007: Edwards Lifesciences Announces First Live Implant Of New BioPhysio Heart Valve
      • 4.1.13 Sep 05, 2007: Edwards Lifesciences Receives CE Mark For Edwards SAPIEN Transcatheter Heart Valve
      • 4.1.14 Aug 29, 2007: Edwards Lifesciences Introduces First Real-Time, Continuous Central Venous Oxygenation Saturation Monitoring Technology For Critically Ill Children
      • 4.1.15 Oct 20, 2006: TCT Program Includes Clinical Presentations Featuring Edwards' Interventional Cardiovascular Technologies
      • 4.1.16 Sep 22, 2005: Edwards Launches New Mitral Magna Heart Valve in Europe
      • 4.1.17 Nov 18, 2003: FDA Approves Edwards Lifesciences' PERIMOUNT Magna Tissue Heart Valve
      • 4.1.18 Oct 16, 2003: New Data Demonstrate Enhanced Durability for Edwards' PERIMOUNT Mitral Valve
    • 4.2 Product Approvals
      • 4.2.1 Sep 03, 2008: Edwards Wins FDA Approval For Mitral Heart Valve
      • 4.2.2 Dec 06, 2007: Edwards Lifesciences Receives European Approval For First Minimally Invasive Surgical Valve Replacement System
      • 4.2.3 Sep 05, 2007: Edwards Lifesciences Receives CE Mark For Edwards SAPIEN Transcatheter Heart Valve
      • 4.2.4 Nov 18, 2003: FDA Approves Edwards Lifesciences' PERIMOUNT Magna Tissue Heart Valve
    • 4.3 Clinical Trials
      • 4.3.1 Oct 14, 2008: Survival Rates Rise In Studies Of Edwards Heart Valves
      • 4.3.2 Oct 13, 2008: Edwards Lifesciences' New Transcatheter Heart Valve Data Demonstrate Positive Results
      • 4.3.3 Sep 15, 2008: Edwards Lifesciences Presents New Transcatheter Heart Valve Data At EACTS
      • 4.3.4 Apr 18, 2008: Edwards Lifesciences Announces First Implants In US Study Of Minimally-Invasive Pulmonic Valve
      • 4.3.5 Jan 29, 2008: Edwards Lifesciences Receives FDA Approval To Add Transapical Delivery System To US Clinical Trial Of Transcatheter Heart Valve
      • 4.3.6 Sep 13, 2007: Edwards Lifesciences Announces First Live Implant Of New BioPhysio Heart Valve
      • 4.3.7 Oct 20, 2006: TCT Program Includes Clinical Presentations Featuring Edwards' Interventional Cardiovascular Technologies
      • 4.3.8 Oct 16, 2003: New Data Demonstrate Enhanced Durability for Edwards' PERIMOUNT Mitral Valve
  • 5 Appendix
    • 5.1 Methodology
      • 5.1.1 Coverage
      • 5.1.2 Secondary Research
      • 5.1.3 Primary Research
      • 5.1.4 Expert Panel Validation
    • 5.2 Contact Us
    • 5.3 About Global Markets Direct
    • 5.4 Disclaimer
  • 1.1 List of Tables
    • Table 1: Edwards Lifesciences Corporation,Key Facts, 2007
    • Table 2: Edwards Lifesciences Corporation Pipeline Products by Equipment Type
    • Table 3: Edwards Lifesciences Corporation Pipeline Products By Development Stage
    • Table 4: Edwards Lifesciences Corporation Pipeline Products By Therapy Area
    • Table 5: Edwards Lifesciences Corporation Pipeline Products By Clinical Trials
    • Table 6: Edwards Lifesciences Corporation Pipeline Products By News Summaries
    • Table 7: MONARC Mitral Repair System, Product Status
    • Table 8: MONARC Mitral Repair System, Product Description
    • Table 9: MONARC Mitral Repair SystemClinical Trials
    • Table 10: MONARC Mitral Repair SystemClinical Trials
    • Table 11: MONARC Mitral Repair System Patent Details
    • Table 12: MOBIUS Leaflet Repair System, Product Status
    • Table 13: MOBIUS Leaflet Repair System, Product Description
    • Table 14: MOBIUS Leaflet Repair SystemClinical Trials
    • Table 15: MOBIUS Leaflet Repair System Patent Details
    • Table 16: Edwards SAPIEN Transcatheter Heart Valve, Product Status
    • Table 17: Edwards SAPIEN Transcatheter Heart Valve, Product Description
    • Table 18: Edwards SAPIEN Transcatheter Heart ValveClinical Trials
    • Table 19: Edwards SAPIEN Transcatheter Heart ValveClinical Trials
    • Table 20: Edwards SAPIEN Transcatheter Heart ValveClinical Trials
    • Table 21: Edwards SAPIEN Transcatheter Heart ValveClinical Trials
    • Table 22: Carpentier-Edwards PERIMOUNT Magna Ease Aortic Heart Valve, Product Status
    • Table 23: Carpentier-Edwards PERIMOUNT Magna Ease Aortic Heart Valve, Product Description
    • Table 24: Carpentier-Edwards PERIMOUNT Magna Ease Aortic Heart Valve Patent Details
    • Table 25: Carpentier-Edwards BioPhysio aortic valve, Product Status
    • Table 26: Carpentier-Edwards BioPhysio aortic valve, Product Description
    • Table 27: Carpentier-Edwards BioPhysio aortic valveClinical Trials
    • Table 28: Ascendra Transapical Delivery System, Product Status
    • Table 29: Ascendra Transapical Delivery System, Product Description
    • Table 30: Ascendra Transapical Delivery SystemClinical Trials
    • Table 31: Ascendra Transapical Delivery System Patent Details
    • Table 32: Carpentier-Edwards Physio II ring, Product Status
    • Table 33: Carpentier-Edwards Physio II ring, Product Description
    • Table 34: Carpentier-Edwards Physio II ring Patent Details
    • Table 35: Carpentier-Edwards PERIMOUNT Magna aortic valve, Product Status
    • Table 36: Carpentier-Edwards PERIMOUNT Magna aortic valve, Product Description
    • Table 37: Carpentier-Edwards PERIMOUNT Magna aortic valve Patent Details
    • Table 38: Continous Glucose Monitoring Device, Product Status
    • Table 39: Continous Glucose Monitoring Device, Product Description
  • 1.2 List of Figures
    • Figure 1: Edwards Lifesciences Corporation Pipeline Products By Equipment Type
    • Figure 2: Edwards Lifesciences Corporation Pipeline Products By Equipment Type
    • Figure 3: Edwards Lifesciences Corporation Pipeline Products By Development Stage
    • Figure 4: Edwards Lifesciences Corporation Pipeline Products By News Summary
    • Figure 5: Global Markets Direct Methodology
+44 20 8816 8548

Ask a question about Edwards Lifesciences Corporation Product Pipeline Analysis

Enter the characters you see in the picture below
Captcha